Related Pages Breast Cancer Home Page NCI's gateway for information about breast cancer. U.S. Task Force: Chemoprevention of Breast Cancer The U.S. Preventive Services Task Force has issued two recommendations concerning the use of prescription medicines such as tamoxifen in the prevention of breast cancer. Estrogen Receptors, Tamoxifen, and Raloxifene Describes the hormone estrogen and its receptor. Explains the relationship of estrogen and its receptor to breast cancer and the risks and benefits of reducing cancer risk with drugs called antiestrogens and selective estrogen receptor molecules (SERMs).

NCI Materials

NCI Press Materials

NCI Cancer Information Service Fact Sheets

En Español

Other Materials

Introduction

One of the largest breast cancer prevention studies ever, the Study of Tamoxifen and Raloxifene, or STAR trial, is underway at more than 500 centers across the United States, Puerto Rico and Canada. The trial includes more than 19,000 postmenopausal women at increased risk of breast cancer and will determine whether the osteoporosis prevention drug raloxifene (Evista®) is as effective in reducing the chance of developing breast cancer as tamoxifen (Nolvadex®).

The trial is closed to further enrollment. Researchers hope to announce results from the trial sometime in 2005.

For more information about STAR:

• In the United States (including Puerto Rico), call the National Cancer Institute's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information in English or Spanish. The number for callers with TTY equipment is 1-800-332-8615.
  
  
• In Canada, call the Canadian Cancer Society's Cancer Information Service at 1-888-939-3333 for information in English or French.
  
  
• The National Surgical Adjuvant Breast and Bowel Project (NSABP) maintains a Web page with information about STAR, including a list of participating sites.

STAR Trial Seeks Volunteers
(Updated: 04/19/2001) - An overview of the purpose and scope of the Study of Tamoxifen and Raloxifene, or STAR trial.

STAR Enrolls 6,139 Women in First Year
(Posted: 07/27/2000) - 16,000 More Women at Increased Risk of Breast Cancer Sought

Second-Year STAR Data: Enrollment Statistics
(Posted: 10/25/2001) - Updated recruitment data from the Study of Tamoxifen and Raloxifene (STAR) trial. Includes link to a table of enrollment by state and province as of October 1, 2001.

Publication of the MORE Trial Results Supports STAR
(Updated: 02/21/2001) - Results from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial brings additional peer-reviewed data to the body of evidence that supports the rationale for the Study of Tamoxifen and Raloxifene (STAR).

Back to Top NCI Press Materials

The Star Trial
(Posted: 10/15/2001) - The Study of Tamoxifen and Raloxifene (STAR), which began in 1999, has just reached its midpoint in recruitment, so BenchMarks interviewed NCI's Leslie G. Ford, M.D., to discuss the progress and promise of the trial.

Back to Top NCI Cancer Information Service Fact Sheets

The Study of Tamoxifen and Raloxifene (STAR): Questions and Answers
A fact sheet about a clinical trial (STAR) comparing the effectiveness and safety of two drugs, tamoxifen and raloxifene, in the prevention of breast cancer.

Back to Top En Español

El Estudio del Tamoxifeno y Raloxifeno (STAR)
(Posted: 05/25/1999) - El Estudio del Tamoxifeno y Raloxifeno (STAR, por sus siglas en inglés), uno de los estudios más importantes realizados para la prevención del cáncer del seno, está ahora reclutando voluntarias en más de 400 centros en los Estados Unidos, Puerto Rico y Canadá.

Preguntas y Respuestas: El Estudio del Tamoxifeno y Raloxifeno (STAR)
(Posted: 04/11/1999) - Preguntas y Respuestas: El Estudio del Tamoxifeno y Raloxifeno

Back to Top Other Materials

Fewer Women Needed to Determine Results of Breast Cancer Prevention Study
(Posted: 10/28/2003) - Researchers from the National Surgical Adjuvant Breast and Bowel Project (NASBP) announced on October 28, 2003, that fewer women are needed than originally thought to complete the Study of Tamoxifen and Raloxifene (STAR) trial.

Prevention and Early Detection Clinical Trials: Opportunities for Primary Care Providers and Their Patients
(Posted: 03/18/2003) - A paper published in the March/April 2003 issue of CA: A Cancer Journal for Clinicians examines some of the barriers to participation in prevention and early detection trials and provides information about various trials now open for enrollment.

Back to Top